Articles tagged with Fibrosis
Researchers have identified activin receptor-interacting protein 2 (ARIP2) as a potential target for treating liver fibrosis. The study found that ARIP2 negatively regulates activin signal pathways, which can help prevent collagen type IV production and alleviate liver damage.
Researchers have found promising results with three new non-invasive imaging tests that can diagnose fibrosis and cirrhosis of the liver without a biopsy. Ultrasound-based transient elastography was accurate in identifying patients with cirrhosis, while MR elastography showed nearly 100% accuracy in detecting any degree of liver fibrosis.
A recent study found that magnetic resonance CAD significantly enhances the diagnostic accuracy of liver fibrosis, outperforming experienced radiologists in detection and grading.
Researchers at Beth Israel Deaconess Medical Center discovered the source of cardiac fibrosis, a stiffening of the heart muscle leading to various cardiac diseases. They found that a bone morphogenic molecule, rhBMP7, can reverse the process, offering a new therapeutic target for patients with heart disease.
Researchers identify distinct genetic profile associated with rapid progression of IPF, highlighting the need for targeted therapies and closer monitoring. The study's findings may lead to the development of biomarkers for disease progression and more effective treatment strategies.
A subset of patients with idiopathic pulmonary fibrosis (IPF) has been found to have a short duration of symptoms before diagnosis and an accelerated clinical course to end-stage disease. This 'rapid progressor' group is characterized by distinct gene expression patterns, which may lead to the development of new therapeutic interventions.
Researchers at Mayo Clinic have developed a new imaging technique called magnetic resonance elastography (MRE) to diagnose liver diseases. MRE accurately measures the hardness or elasticity of the liver, enabling non-invasive diagnosis of fibrosis and cirrhosis.
Researchers developed a non-invasive method to predict advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) using routine clinical and laboratory values. The study found that age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio were independent indicators of advanced liver fibrosis.
A UCLA study reports that over half of patients with idiopathic pulmonary fibrosis improved their walking distance by at least 20% after taking Viagra. The medication may help breathing by opening or dilating blood vessels to allow more blood flow to the lungs.
A new study found that a series of simple blood tests can accurately diagnose liver fibrosis in patients with chronic hepatitis C. The FibroIndex was more accurate than two other indices and showed promise as a non-invasive alternative to liver biopsy.
Researchers at Rice University have identified a naturally occurring blood protein called serum amyloid P, or SAP, which prevents the formation of life-threatening scar tissue in fibrotic diseases. The discovery has promising results in lab animal tests and could eventually save thousands of lives with human clinical trials.
Researchers discovered that imatinib mesylate inhibits the synthesis of extracellular matrix proteins and prevents tissue fibrosis in patients with systemic sclerosis. The study provides promising results for a new treatment approach, but more extensive studies are needed to confirm its efficacy.
Mayo Clinic researchers have developed MR Elastography (MRE), a new technique for measuring liver elasticity using MRI. This non-invasive method shows great promise for detecting liver fibrosis, which can lead to cirrhosis if left untreated.
Familial idiopathic pulmonary fibrosis (IPF) is linked to the ELMOD2 gene, which regulates apoptosis and cell migration. The study identified a susceptibility haplotype associated with an increased risk of IPF, supporting ELMOD2 as a prime candidate gene.
Researchers at U-M aim to develop new treatments for idiopathic pulmonary fibrosis (IPF) by understanding the role of fibrocytes and signaling pathways involved in the disease. They found that lipid mediators called cysteinyl leukotrienes may be responsible for inappropriate activation of fibrocytes.
A new study reveals that combined contrast enhanced MRI (CCE-MRI) closely matches the staging of non-alcoholic fatty liver disease (NAFLD) using conventional pathology. CCE-MRI offers a safer alternative to invasive liver biopsy, directly visualizing fibrosis and detecting liver cancers simultaneously.
A University of Pittsburgh study suggests that standard anti-inflammatory therapy may not be appropriate for many interstitial lung disease patients. The research used DNA microarray chip technology to distinguish between gene expression patterns of different types of interstitial lung diseases, revealing two vastly different condition...
Researchers Phillipe Besnard and colleagues pinpoint CD36 as the sensor for lipid detection in the oral cavity. They show that lingual stimulation of CD36 influences behavioral and digestive physiology. The findings suggest a potential pathway mediating fat taste, which may contribute to obesity risk through feeding dysregulation.
A new study identifies genetic susceptibility as a significant risk factor for pulmonary fibrosis. The condition, which can be triggered by smoking and other factors, causes inflammation and scarring in the lungs. Researchers also explored a more accurate blood test to detect latent tuberculosis infection.
Researchers discovered a genetic basis for idiopathic pulmonary fibrosis, with those having ever smoked cigarettes being 3.6 times more likely to develop the disease. The study also highlights the importance of avoiding cigarette smoking as a preventive measure for this devastating lung condition.
A new laboratory test has been developed to identify patients at high risk of developing cirrhosis after a liver transplant due to hepatitis C. The test targets hepatic stellate cells, which can produce collagen leading to scarring in infected patients.
Researchers identified alpha-smooth muscle actin (alpha-SMA) as a reliable marker for predicting fibrosis development after liver transplant. Studies showed that HSC activation was associated with advanced fibrosis, suggesting a potential biomarker for early intervention and treatment.
Researchers found a common genetic defect that prevents proper lung repair, increasing risk of idiopathic pulmonary fibrosis in families with a history of the disease. Smoking is also a major contributor to the disease, particularly among those with a family history.
A study identified osteopontin as a protein more prevalent in lungs of patients with idiopathic pulmonary fibrosis. The protein increased cell proliferation and movement involved in lung fibrosis, offering potential new treatment targets.
Researchers found that nicotine caused a significant increase in atrial interstitial fibrosis and electrical remodeling in hearts with myocardial infarction, leading to atrial flutter. The study suggests a causal link between nicotine and atrial flutter, potentially informing new therapeutic strategies.
Researchers found that transplanted bone marrow cells reduced liver fibrosis in mice treated with carbon tetrachloride. The treatment also improved survival rates and increased serum albumin levels, suggesting a new concept for treating liver fibrosis.
A novel AT2R gene transfer approach has been shown to prevent hypertension-related enlarged heart, cardiac fibrosis. The study found that the procedure prevented the heart from enlarging and prevented thickening of the ventricular walls.
Researchers found elevated caspase levels in HCV patients with normal aminotransferase levels, associated with higher stages of liver fibrosis. The study suggests that measuring caspase-mediated CK-18 cleavage in serum may be a more sensitive method to detect liver fibrosis in chronic HCV infection.
Pulmonary fibrosis occurs when normal lung tissue is replaced with thick scar tissue, impairing oxygen flow. Researchers have discovered that TGF-beta causes apoptosis in epithelial cells before fibrosis develops, paving the way for potential treatments by blocking cell death.
Researchers found that a specific adult stem cell travels to the lung through the bloodstream and produces collagen, leading to scar tissue formation. Blocking this mechanism may reduce pulmonary fibrosis, offering new treatments for related disorders like rheumatoid arthritis.
Researchers at Yale University demonstrate that OspC is critical for Borrelia burgdorferi's ability to invade tick salivary glands and be transmitted to humans. Meanwhile, studies on hereditary spastic paraplegia and idiopathic pulmonary fibrosis reveal potential new targets for treatment.
Researchers have discovered that bone marrow-derived stem cells are present in the lungs of mice with pulmonary fibrosis. This finding suggests a new approach to treating the disease using stem cell therapy. Understanding how these stem cells engraft and interact with the lung tissue could lead to improved treatment outcomes.
Researchers developed a new composite score combining CT imaging and pulmonary function testing to assess treatment effects in young cystic fibrosis patients. A new test was also developed to predict increased mortality risk in idiopathic interstitial pneumonia patients with significant decline in pulmonary function.
A new Composite Physiologic Index (CPI) effectively tracks pulmonary fibrosis in patients and provides a more accurate prognostic indicator for interstitial pneumonia. Additionally, researchers explore the potential of stem cells to treat acute lung injury and its severe form, ARDS.
A randomized controlled trial found that sildenafil reduced pulmonary blood resistance, a key indicator of pulmonary hypertension. The study suggests sildenafil could be a promising candidate for long-term treatment of secondary pulmonary hypertension in lung fibrosis. Controlled trials are needed to confirm the findings.